Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2010-05-19 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2010-05-19 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a press release about a joint initiative between the company's charitable organization and the Vatican's Pontifical Council for Culture's charitable organization. There are no financial statements, earnings data, or detailed management discussion. The document is short (4347 characters) and primarily serves to disclose a specific event rather than provide a comprehensive financial report or management analysis. It is not an earnings release, annual report, or interim report. It is also not a regulatory certification or officer attestation. The document fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2010-05-19 English
8-K Filing
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a Common Stock Purchase Agreement entered into by the company, detailing terms of a financing arrangement with Commerce Court Small Cap Value Fund, Ltd. It includes specifics about share purchase commitments, pricing, and regulatory compliance with FINRA. The document does not contain financial statements or comprehensive financial performance data, nor is it an earnings release or annual/interim report. It is an announcement of a capital raising transaction and related agreements. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2010-05-19 English
424B2 Filing
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(2) related to a shelf registration statement (Registration No. 333-166169) for NeoStem, Inc. It details the offering of various securities including common stock, preferred stock, debt securities, warrants, and units, with an aggregate offering price of up to $45,000,000. The document includes descriptions of the securities, risk factors, use of proceeds, and other offering details. It is not a financial report, earnings release, or management discussion, but rather a formal offering document for capital raising. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities.
2010-05-19 English
4 Filing
Director's Dealing
2010-05-19 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates that shareholders should know about. The text indicates it is providing an update on a subsidiary following the end of the first quarter of the year, and it includes a press release as an exhibit. The document is relatively short (4224 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is an announcement of an event or update rather than a full financial report. Therefore, it does not qualify as an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not a certification, management change, or other specific category. Given the nature of Form 8-K filings and the content, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2010-05-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.